The pharmaceutical industry is navigating a profound transformation into what we call “Pharma 3.0.” We explore how companies are adapting their commercial models in response.
Commercial excellence in pharma 3.0
Firepower and Growth Gap Report 2014
10 things to know about the 2013 IPO class
Insights from 30 years of biotech IPOs
Big pharma in a competitive M&A environment
Worldwide research and development incentive guide
Pulse of the industry - medical technology report 2013
Cash on prescription 2013
Beyond Borders: global biotech report 2013
Finding sustainability in biotechnology, pharmaceutical and medical technology
Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.
Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.
We cover key issues in these areas:
More than any other technology, biotechnology has the potential to alter our lives in a positive way. And by achieving this potential, today’s biotech companies are delivering new levels of health, prosperity and sustainability — across the world.
But with uncertain capital markets, increasing regulation, growing pricing pressures, competition for acquisitions and an evolving health care environment around the world, this sector faces unprecedented challenges.
We have been a pioneering presence in the biotechnology industry. We were the first professional services firm to build a practice dedicated to serving your industry.
We’ve stayed committed to your business with our leading reports and our network of knowledgeable professionals.
So it’s not surprising that we serve more biotech companies than any other professional services firm — by a wide margin.
Take a closer look:
- Beyond Borders: global biotech report 2013
- German biotechnology report 2013 [English]
- Progressions 2012: health care everywhere
- Progressions 2011: Pharma 3.0
- Beyond borders: global biotechnology report 2012
- What Europe has to offer biotechnology companies
- 2013 Italian Biotechnology Report: BioInItaly
- Swiss biotechnology report 2013
Pharmaceutical companies are facing great changes to the industry — emerging science, new products and services, shifting demographics, evolving regulations, transforming business models and increased stakeholder expectations. We are helping pharmaceutical companies around the globe to address the challenges presented by this new world we call Pharma 3.0.
We also publish a series of reports to bring you clear insights on accounting, tax, transaction, compliance and business process issues, as well as our annual report on pharmaceutical industry trends, Progressions. Our thought leadership helps you navigate the shifting global landscape and grow your business — the new business imperative of improving health outcomes.
Today we stand on the cusp of the next big wave in improvements in health outcomes – driven not just by new products, but by behavioral change. We are moving to a world in which more emphasis will be on gathering evidence to identify interventions that are most effective at improving health outcomes, and then realigning the behavior of all stakeholders — patients, providers, manufacturers and others — around these interventions.
Take a closer look:
- Medical technology
Fundamental drivers — from aging populations and increasingly prevalent chronic diseases to expanding needs for lifestyle medical procedures — suggest demand for medical technology products should be robust for years to come.
Still, the road ahead is littered with risks and challenges. Within an industry that requires constant innovation, you’re under pressure to demonstrate value for the products you develop, comply with increased regulations and satisfy the demanding new consumer-turned-competitor.
Not only are we the firm of choice for medtechs entering the public markets, we also audit more medtech companies that are tracked by the Russell 3000 and Standard & Poor’s than any other professional services firm.
From venture funding and IPOs to initial product launches and global expansions, we have the proven experience to help medical technology organizations navigate every critical stage of their business life cycle.
Take a closer look: